Regeneron Receives Expanded Authorized Use from FDA for Antibody COVID-19 Treatment

The expanded authorization from FDA enables the use of Regeneron Pharmaceuticals’ REGEN-COV antibody cocktail therapy for post-exposure prophylaxis in certain people exposed to SARS-CoV-2.